THREE firms, Natural Franchises Pty Ltd, SARMs International Pty Ltd, and Smart Labs Pty Ltd, and their sole director, Christopher Ramsey, have entered guilty pleas to more than 200 offences related to the manufacture, supply and promotion of unapproved therapeutic goods.
The Therapeutic Goods Administration (TGA) revealed that it conducted an extensive investigation in 2019 and 2020, which found Ramsey and his companies were manufacturing and selling selective androgen receptor modulators (SARMs) and nootropics, that were not included on the Australian Register of Therapeutic Goods (ARTG), in accordance with the Therapeutic Goods Act 1989.
The regulator described SARMs as "experimental medicines claimed to build muscle mass and bone density", noting they are scheduled as Prescription-Only medications in Australia.
In addition to the promotion and sale of products not listed on the ARTG, the TGA's investigation found that a product supplied by one of Ramsey's companies, Natural Franchises Pty Ltd, contained the Schedule 10 ingredient, Cardarine, which is prohibited in Australia due to being a potential carcinogen.
"Sentencing for this matter is set for hearing at Downing Centre Local Court in Sydney on 15 and 17 Mar 2023," the TGA said.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Nov 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Nov 22
